| scholarly article | Q13442814 |
| P50 | author | Paul Workman | Q7154482 |
| Nicola E A Chessum | Q89635496 | ||
| Elisa Pasqua | Q89635498 | ||
| Mark Stubbs | Q89635502 | ||
| Paul A Clarke | Q38546651 | ||
| Keith Jones | Q42289984 | ||
| Matthew D Cheeseman | Q42289987 | ||
| Birgit Wilding | Q59559269 | ||
| Bugra Ozer | Q86928483 | ||
| Rosemary Burke | Q87855031 | ||
| Ian Collins | Q89426612 | ||
| P2093 | author name string | John J Caldwell | |
| Swee Y Sharp | |||
| Martin Rowlands | |||
| Meirion Richards | |||
| P Craig McAndrew | |||
| Giampiero Colombano | |||
| P2860 | cites work | Pirin is an iron-dependent redox regulator of NF-κB | Q24294125 |
| Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery | Q24302241 | ||
| Target engagement in lead generation | Q26827296 | ||
| Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities | Q27640584 | ||
| Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide | Q27684738 | ||
| Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase | Q27704179 | ||
| Global quantification of mammalian gene expression control | Q28238103 | ||
| How does multiple testing correction work? | Q28267689 | ||
| Ubiquitin-independent proteasomal degradation | Q28290917 | ||
| DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation | Q28830958 | ||
| Cupins: the most functionally diverse protein superfamily? | Q30164325 | ||
| Monitoring protein interactions in living cells with fluorescence lifetime imaging microscopy | Q30411241 | ||
| Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand | Q30729180 | ||
| Rapid palladium-catalyzed synthesis of esters from aryl halides utilizing Mo(CO)(6) as a solid carbon monoxide source | Q31149344 | ||
| Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors | Q31941605 | ||
| A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors | Q34067085 | ||
| Proteasome inhibitors: from research tools to drug candidates | Q34341985 | ||
| Biochemical mechanisms of drug action: what does it take for success? | Q34344862 | ||
| Tracking cancer drugs in living cells by thermal profiling of the proteome | Q34441561 | ||
| Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. | Q34478968 | ||
| Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. | Q34479551 | ||
| Catalytic in vivo protein knockdown by small-molecule PROTACs. | Q34480735 | ||
| Target engagement and drug residence time can be observed in living cells with BRET. | Q34503961 | ||
| Induced protein degradation: an emerging drug discovery paradigm | Q34545841 | ||
| DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase | Q34641190 | ||
| Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | Q34663680 | ||
| In vitro trans-monolayer permeability calculations: often forgotten assumptions | Q35595393 | ||
| Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. | Q35778631 | ||
| Small-Molecule PROTACS: New Approaches to Protein Degradation | Q35891557 | ||
| Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development. | Q36149268 | ||
| Features of selective kinase inhibitors | Q36173396 | ||
| Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. | Q36238589 | ||
| Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules. | Q36242161 | ||
| In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs). | Q36268420 | ||
| Structural basis of PROTAC cooperative recognition for selective protein degradation | Q36306106 | ||
| Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway | Q36309724 | ||
| Thalidomide metabolism and hydrolysis: mechanisms and implications | Q36569878 | ||
| A comprehensive mathematical model for three-body binding equilibria | Q37029337 | ||
| Activity-based protein profiling: from enzyme chemistry to proteomic chemistry | Q37119021 | ||
| Measuring and interpreting the selectivity of protein kinase inhibitors | Q37537075 | ||
| Colloidal drug formulations can explain "bell-shaped" concentration-response curves | Q37701412 | ||
| Determining target engagement in living systems | Q37732146 | ||
| Applications of Fluorine in Medicinal Chemistry | Q38552042 | ||
| Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy | Q38631145 | ||
| Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes | Q38666368 | ||
| Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds | Q38673230 | ||
| Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. | Q38710711 | ||
| Small-Molecule Target Engagement in Cells | Q38799360 | ||
| Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. | Q38817737 | ||
| Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity | Q39241734 | ||
| Impact of linker length on the activity of PROTACs | Q39648105 | ||
| Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity | Q40362761 | ||
| Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery | Q41256404 | ||
| Pirin regulates epithelial to mesenchymal transition independently of Bcl3-Slug signaling. | Q41438372 | ||
| Multiple hypothesis testing in proteomics: a strategy for experimental work. | Q42173706 | ||
| Quantitating drug-target engagement in single cells in vitro and in vivo | Q42275555 | ||
| Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. | Q43770038 | ||
| Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. | Q45858607 | ||
| ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling | Q46707032 | ||
| Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation. | Q48000406 | ||
| Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen | Q48125728 | ||
| Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. | Q48151643 | ||
| How Big Is Too Big for Cell Permeability? | Q48197834 | ||
| Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex | Q48237303 | ||
| Beyond Overton's rule: quantitative modeling of passive permeation through tight cell monolayers. | Q48563848 | ||
| Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). | Q50932257 | ||
| An exact correction to the "Cheng-Prusoff" correction. | Q52576210 | ||
| A Perspective on the Kinetics of Covalent and Irreversible Inhibition | Q60962649 | ||
| Finding the sweet spot: the role of nature and nurture in medicinal chemistry | Q84032484 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 918-933 | |
| P577 | publication date | 2018-01-05 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766) | |
| P478 | volume | 61 |
| Q92758130 | A critical evaluation of the approaches to targeted protein degradation for drug discovery |
| Q92042152 | Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay |
| Q90719868 | Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality |
| Q92189593 | Developing degraders: principles and perspectives on design and chemical space |
| Q58417674 | Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships |
| Q89996627 | Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules |
| Q90186445 | PROTACs- a game-changing technology |
| Q92310282 | PROTACs: great opportunities for academia and industry |
| Q92758119 | PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future |
| Q89518885 | Principle and design of pseudo-natural products |
| Q64885983 | Privileged Structures and Polypharmacology within and between Protein Families. |
| Q92512732 | Protein-slaying drugs could be the next blockbuster therapies |
| Q95923717 | RAC1 as a Therapeutic Target in Malignant Melanoma |
| Q96431675 | Targeted protein degradation as a powerful research tool in basic biology and drug target discovery |
| Q59287278 | The size matters? A computational tool to design bivalent ligands |
Search more.